Literature DB >> 1759121

Chronic gastritis: progression of inflammation and atrophy in a six-year endoscopic follow-up of a random sample of 142 Estonian urban subjects.

K Villako1, M Kekki, H I Maaroos, P Sipponen, R Uibo, R Tammur, A Tamm.   

Abstract

To study the prevalence and course of chronic gastritis (CG), 142 adult subjects collected at random from an Estonian urban area were endoscopically and bioptically examined at a six-year interval. The histology of the antral and corpus mucosae was evaluated by grading gastritis without ("superficial gastritis"; SG) and with atrophy ("atrophic gastritis"; AG) into mild, moderate and severe categories. A total of 135 (95%) and 139 (98%) subjects showed CG in the 1st and 2nd examinations, respectively. The CG healed in one subjects (0.7%), and in 5 out of 7 subjects with normal stomach in the 1st examination the CG started during the follow-up. No change in the severity of CG was seen in 24% of subjects with gastritis in the 1st examination. The main trend of CG was a slow, "one-step progression" in severity of inflammation and appearance of atrophy and intestinal metaplasia. Inflammation progressed significantly, especially in the young age groups and in the antrum in particular. The prevalence of AG increased linearly with age in corpus (mean annual risk 1.25%). Parietal cell antibodies (PCA) were found in 2 subjects in the 1st examination, and a further 2 subjects developed these antibodies later. Three of four PCA-positive subjects belonged to a subgroup of 8 elderly subjects who had corpus AG at both examinations and who also showed normal or normalizing mucosa in the antrum. It is concluded that CG is a slowly progressive disease advancing with time and, once started, rarely healing spontaneously.

Entities:  

Mesh:

Year:  1991        PMID: 1759121     DOI: 10.3109/00365529109104000

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  17 in total

1.  Screening for early gastric cancer.

Authors:  K E L McColl
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 2.  Age-related changes in cobalamin (vitamin B12) handling. Implications for therapy.

Authors:  H Nilsson-Ehle
Journal:  Drugs Aging       Date:  1998-04       Impact factor: 3.923

3.  Gastric intestinal metaplasia: subtypes and natural history.

Authors:  H M El-Zimaity; J Ramchatesingh; M A Saeed; D Y Graham
Journal:  J Clin Pathol       Date:  2001-09       Impact factor: 3.411

Review 4.  Gastric atrophy, diagnosing and staging.

Authors:  Hala M T El-Zimaity
Journal:  World J Gastroenterol       Date:  2006-09-28       Impact factor: 5.742

5.  The long term results of endoscopic surveillance of premalignant gastric lesions.

Authors:  J L Whiting; A Sigurdsson; D C Rowlands; M T Hallissey; J W L Fielding
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

Review 6.  Does gastric atrophy exist in children?

Authors:  Georges Dimitrov; Frederic Gottrand
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

7.  Ten year follow up study of lymphocytic gastritis: further evidence on Helicobacter pylori as a cause of lymphocytic gastritis and corpus gastritis.

Authors:  S Niemelä; T Karttunen; T Kerola; R Karttunen
Journal:  J Clin Pathol       Date:  1995-12       Impact factor: 3.411

8.  A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia.

Authors:  M Dinis-Ribeiro; C Lopes; A da Costa-Pereira; M Guilherme; J Barbosa; H Lomba-Viana; R Silva; L Moreira-Dias
Journal:  J Clin Pathol       Date:  2004-02       Impact factor: 3.411

9.  Helicobacter pylori-induced damage to the gastric mucosa is not modulated by previous vagotomy or medical treatment of peptic ulcer disease: a comparative study of vagotomized patients, medically treated peptic ulcer patients and community control subjects.

Authors:  Rolv-Ole Lindsetmo; Tor Jac Eide; Roar Johnsen; Arthur Revhaug
Journal:  World J Surg       Date:  2008-10       Impact factor: 3.352

10.  Helicobacter pylori and early gastric cancer.

Authors:  M E Craanen; P Blok; W Dekker; G N Tytgat
Journal:  Gut       Date:  1994-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.